ABSTRACT
Among cancers of different origin, multiple myeloma (MM) has carved out a position of prominence, as an effective model system to test and validate leading therapeutic compounds. Indeed, several drugs now in clinical practice were first successfully tested in MM, and then their use extended to other hematological and epithelial tumors.
